Curcumin abrogates LPS-induced proinflammatory cytokines in RAW 264.7 macrophages. Evidence for novel mechanisms involving SOCS-1, -3 and p38 MAPK

Archives of Oral Biology

Volumn 58, Issue 10, 2013, Pages 1309-1317

  Guimarães, Morgana Rodrigues ^a   Leite, Fábio Renato Manzoli ^a,c   Spolidorio, Luís Carlos ^a   Kirkwood, Keith Lough ^b   Rossa Jr , Carlos ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

Author keywords

Cell signalling; Curcumin; Cytokines; Innate immunity; MAPK; NF B; SOCS

Indexed keywords

CURCUMA LONGA; ESCHERICHIA COLI; MURINAE;

CURCUMIN; CYCLOOXYGENASE 2; CYTOKINE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PTGS2 PROTEIN, MOUSE; SOCS1 PROTEIN, MOUSE; SUPPRESSOR OF CYTOKINE SIGNALING; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; CELL SIGNALLING; IMMUNOLOGY; INNATE IMMUNITY; MACROPHAGE; MAPK; MOUSE; NF-KB; SIGNAL TRANSDUCTION; SOCS;

CELL SIGNALLING; CURCUMIN; CYTOKINES; INNATE IMMUNITY; MAPK; NF-KB; SOCS;

ANIMALS; CURCUMIN; CYCLOOXYGENASE 2; CYTOKINES; IMMUNITY, INNATE; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA, MESSENGER; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84888053344     PISSN: 00039969     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archoralbio.2013.07.005     Document Type: Article

References (46)

1. Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. British Journal of Cancer 2004 Mar 8;90(5):1011-5.
2. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clinical Cancer Research 2001 Jul;7(7):1894-900.
3. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clinical Cancer Research 2004 Oct 15;10(20):6847-54.
4. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian Journal of Medical Research 1980;71(April):632-4.
5. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Digestive Diseases and Sciences 2005;50(November (11)):2191-3.
6. Bundy R, Walker AF, Middleton RW, Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. Journal of Alternative and Complementary Medicine 2004;10(December (6)):1015-8.
7. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clinical Gastroenterology and Hepatology 2006;4(December 12):1502-6.
8. Heng MC, Song MK, Harker J, Heng MK. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. British Journal of Dermatology 2000;143(November (5)):937-49.
9. Brouet I, Ohshima H. Curcumin, an anti-tumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochemical and Biophysical Research Communications 1995;206(January (2)):533-40.
10. Lantz RC, Chen GJ, Solyom AM, Jolad SD, Timmermann BN. The effect of turmeric extracts on inflammatory mediator production. Phytomedicine 2005;12(June (6-7)):445-52.
11. Saja K, Babu MS, Karunagaran D, Sudhakaran PR. Anti-inflammatory effect of curcumin involves downregulation of MMP-9 in blood mononuclear cells. International Immunopharmacology 2007;7(December (13)):1659-67.
12. Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclooxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: implications for the treatment of osteoarthritis. Biochemical Pharmacology 2007;73(May (9)):1434-45.
13. Surh YJ. Anti-tumor promoting potential of selected spice ingredients with antioxidative and anti-inflammatory activities: a short review. Food and Chemical Toxicology 2002;40(August (8)):1091-7.
14. Swarnakar S, Ganguly K, Kundu P, Banerjee A, Maity P, Sharma AV. Curcumin regulates expression and activity of matrix metalloproteinases 9 and 2 during prevention and healing of indomethacin-induced gastric ulcer. Journal of Biological Chemistry 2005;280(March (10)):9409-15.
15. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA. Phylogenetic perspectives in innate immunity. Science 1999;284(May (5418)):1313-8.
16. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annual Review of Immunology 1998;16:225-60.
17. Kim YS, Ahn Y, Hong MH, Joo SY, Kim KH, Sohn IS, et al. Curcumin attenuates inflammatory responses of TNF-alpha-stimulated human endothelial cells. Journal of Cardiovascular Pharmacology 2007;50(July (1)):41-9.
18. Bharti AC, Takada Y, Aggarwal BB. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. Journal of Immunology 2004;172(May (10)):5940-7.
19. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. Journal of Immunology 2003;171(October (7)):3863-71.
20. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Research 2003;23(January-February (1A)):363-98.
21. Rafiee P, Nelson VM, Manley S, Wellner M, Floer M, Binion DG, et al. Effect of curcumin on acidic pH-induced expression of IL-6 and IL-8 in human esophageal epithelial cells (HET-1A): role of PKC, MAPKs, and NF-kappaB. American Journal of Physiology - Gastrointestinal and Liver Physiolology 2009;296 (February (2)):G388-98.
22. Park SH, Kim KE, Hwang HY, Kim TY. Regulatory effect of SOCS on NF-kappaB activity in murine monocytes/macrophages. DNA and Cell Biology 2003;22(February (2)):131-9.
23. Yoshimura A. Negative regulation of cytokine signaling. Clinical Reviews in Allergy and Immunology 2005;28(June (3)):205-20.
24. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997;387(June (6636)):917-21.
25. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997;387 (June (6636)):921-4.
26. Naka T, Fujimoto M, Tsutsui H, Yoshimura A. Negative regulation of cytokine and TLR signalings by SOCS and others. Advances in Immunology 2005;87:61-122.
27. Kinjyo I, Inoue H, Hamano S, Fukuyama S, Yoshimura T, Koga K, et al. Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. Journal of Experimental Medicine 2006;203(April (4)):1021-31.
28. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity 2008;28(April (4)):477-87.
29. Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS, et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999;98(September (5)):597-608.
30. Egan PJ, Lawlor KE, Alexander WS, Wicks IP. Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation. Journal of Clinical Investigation 2003;111(March (6)):915-24.
31. de Hooge AS, van de Loo FA, Koenders MI, Bennink MB, Arntz OJ, Kolbe T, et al. Local activation of STAT-1 and STAT-3 in the inflamed synovium during zymosan-induced arthritis: exacerbation of joint inflammation in STAT-1 gene-knockout mice. Arthritis and Rheumatism 2004;50(June (6)):2014-23.
32. Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. Journal of Clinical Investigation 2001;108(December (12)):1781-8.
33. Fultz MJ, Barber SA, Dieffenbach CW, Vogel SN. Induction of IFN-gamma in macrophages by lipopolysaccharide. International Immunology 1993; 5(November (11)):1383-92.
34. Jones BW, Means TK, Heldwein KA, Keen MA, Hill PJ, Belisle JT, et al. Different Toll-like receptor agonists induce distinct macrophage responses. Journal of Leukocyte Biology 2001;69(June (6)):1036-44.
35. Fang H, Pengal RA, Cao X, Ganesan LP, Wewers MD, Marsh CB, et al. Lipopolysaccharide-induced macrophage inflammatory response is regulated by SHIP. Journal of Immunology 2004; 173(July (1)):360-6.
36. Gauley J, Pisetsky DS. The release of microparticles by RAW 264.7 macrophage cells stimulated with TLR ligands. Journal of Leukocyte Biology 2010;87(June (6)):1115-23.
37. Ji G, Zhang Y, Yang Q, Cheng S, Hao J, Zhao X, et al. Genistein suppresses LPS-induced inflammatory response through inhibiting NF-kappaB following AMP kinase activation in RAW 264.7 macrophages. PLoS ONE 2012;7(12):e53101.
38. Chen D, Nie M, Fan MW, Bian Z. Anti-inflammatory activity of curcumin in macrophages stimulated by lipopolysaccharides from Porphyromonas gingivalis. Pharmacology 2008;82(4):264-9.
39. Abe Y, Hashimoto S, Horie T. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacological Research 1999;39(January (1)):41-7.
40. Jain SK, Rains J, Croad J, Larson B, Jones K. Curcumin supplementation lowers TNF-alpha, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-alpha, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. Antioxidants and Redox Signalling 2009;11 (February (2)):241-9.
41. Huang TS, Lee SC, Lin JK. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proceedings of the National Academy of Sciences of the United States of America 1991;88(June (12)):5292-6.
42. Moon DO, Jin CY, Lee JD, Choi YH, Ahn SC, Lee CM, et al. Curcumin decreases binding of Shiga-like toxin-1B on human intestinal epithelial cell line HT29 stimulated with TNF-alpha and IL-1beta: suppression of p38, JNK and NF-kappaB p65 as potential targets. Biological and Pharmaceutical Bulletin 2006;29 (July (7)):1470-5.
43. Wang SL, Li Y, Wen Y, Chen YF, Na LX, Li ST, et al. Curcumin, a potential inhibitor of up-regulation of TNF-alpha and IL-6 induced by palmitate in 3T3-L1 adipocytes through NF-kappaB and JNK pathway. Biomedical and Environmental Sciences 2009;22(February (1)):32-9.
44. Binion DG, Otterson MF, Rafiee P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 2008;57(November (11)):1509-17.
45. Saydmohammed M, Joseph D, Syed V. Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. Journal of Cellular Biochemistry 2010;110(May (2)):447-56.
46. Strebovsky J, Walker P, Lang R, Dalpke AH. Suppressor of cytokine signaling 1 (SOCS1) limits NFkappaB signaling by decreasing p65 stability within the cell nucleus. FASEB Journal 2011;25(March (3)):863-74.